Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost Benefits Optimization Solutions, announced today that it has selected CVS Caremark at its pharmacy ...

The company that sells Ozempic and Wegovy, drugs known for promoting easy weight loss, is now selling the products at Costco. Novo Nordisk, which manufactures the injectable pen semaglutide drugs for ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications. The company announced that through the end ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing ...

The federal government has announced the results of the latest round of Medicare drug price negotiations: 15 lower drug prices for Medicare to go into effect in 2027. Medicare will get a 71% discount ...

Novo Nordisk NOVO.B2.54%increase; green up pointing triangle filed for U.S. approval of a higher dose of its Wegovy weight-loss injection, with a decision expected within a month or two. The Danish ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide 2.4 mg was tied to reduced risk for major adverse cardiovascular events in certain patients with ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription drugs, including popular weight-loss medications Ozempic and Wegovy, asthma ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med ...

The new prices will take effect in 2027, and the negotiated prices include a monthly cost of $274 for Novo Nordisk’s (NYSE: NVO) popular GLP-1 drug, semaglutide, sold as Wegovy, Ozempic, and Rybelsus.

Over half of people who started using semaglutide (Wegovy) for weight loss ditched it within the first 12 months, a Danish population-based study found. Among 77,310 adults without diabetes who began ...